These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37384596)

  • 1. Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): An open-label randomized controlled trial.
    Ma X; Yang F; Wu J; Xu B; Jiang M; Sun Y; Sun C; Yu Y; Xu D; Xiao L; Ren C; Chen C; Ye Z; Liang J; Lin J; Chen W
    PLoS Med; 2023 Jun; 20(6):e1004249. PubMed ID: 37384596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial.
    Devauchelle-Pensec V; Carvajal-Alegria G; Dernis E; Richez C; Truchetet ME; Wendling D; Toussirot E; Perdriger A; Gottenberg JE; Felten R; Fautrel BJ; Chiche L; Hilliquin P; Le Henaff C; Dervieux B; Direz G; Chary-Valckenaere I; Cornec D; Guellec D; Marhadour T; Nowak E; Saraux A
    JAMA; 2022 Sep; 328(11):1053-1062. PubMed ID: 36125471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial.
    Saraux A; Le Henaff C; Dernis E; Carvajal-Alegria G; Tison A; Quere B; Petit H; Felten R; Jousse-Joulin S; Guellec D; Marhadour T; Kervarrec P; Cornec D; Querellou S; Nowak E; Souki A; Devauchelle-Pensec V
    Lancet Rheumatol; 2023 Dec; 5(12):e728-e735. PubMed ID: 38251563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concordance and agreement between different activity scores in polymyalgia rheumatica.
    D'Agostino J; Souki A; Lohse A; Carvajal Alegria G; Dernis E; Richez C; Truchetet ME; Wendling D; Toussirot E; Perdriger A; Gottenberg JE; Felten R; Fautrel B; Chiche L; Hilliquin P; Le Henaff C; Dervieux B; Direz G; Chary-Valckenaere I; Cornec D; Guellec D; Marhadour T; Nowak E; Saraux A; Devauchelle-Pensec V
    RMD Open; 2024 Mar; 10(1):. PubMed ID: 38490696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trial.
    Marsman DE; Bolhuis TE; den Broeder N; den Broeder AA; van der Maas A
    Trials; 2022 Apr; 23(1):318. PubMed ID: 35428320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucocorticoid treatment and clinical outcomes in patients with polymyalgia rheumatica: A cohort study using routinely collected health data.
    Tanaka Y; Tanaka S; Fukasawa T; Inokuchi S; Uenaka H; Kimura T; Takahashi T; Kato N
    Joint Bone Spine; 2024 May; 91(3):105680. PubMed ID: 38143016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study.
    Devauchelle-Pensec V; Berthelot JM; Cornec D; Renaudineau Y; Marhadour T; Jousse-Joulin S; Querellou S; Garrigues F; De Bandt M; Gouillou M; Saraux A
    Ann Rheum Dis; 2016 Aug; 75(8):1506-10. PubMed ID: 26929219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab monotherapy for polymyalgia rheumatica: A prospective, single-center, open-label study.
    Chino K; Kondo T; Sakai R; Saito S; Okada Y; Shibata A; Kurasawa T; Okuyama A; Takei H; Amano K
    Int J Rheum Dis; 2019 Dec; 22(12):2151-2157. PubMed ID: 31625288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial.
    Kreiner F; Galbo H
    Arthritis Res Ther; 2010; 12(5):R176. PubMed ID: 20854662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity.
    Cimmino MA; Parodi M; Montecucco C; Caporali R
    BMC Musculoskelet Disord; 2011 May; 12(1):94. PubMed ID: 21569559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial.
    Bolhuis TE; Marsman DE; den Broeder AA; den Broeder N; van der Maas A
    Lancet Rheumatol; 2023 Apr; 5(4):e208-e214. PubMed ID: 38251523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of JAK Inhibitors versus DMARDs in the Treatment of Polymyalgia Rheumatica in China.
    Gu J; Yang M; Zhang B; Wang H
    Int J Gen Med; 2023; 16():2981-2986. PubMed ID: 37465555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing polymyalgia rheumatica activity when C-reactive protein is unavailable or uninterpretable.
    Devauchelle-Pensec V; Saraux L; Berthelot JM; De Bandt M; Cornec D; Guellec D; Marhadour T; Jousse-Joulin S; Gouillou M; Saraux A
    Rheumatology (Oxford); 2018 Apr; 57(4):666-670. PubMed ID: 29346621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophil to lymphocyte ratio predicts glucocorticoid resistance in polymyalgia rheumatica.
    Owen CE; McMaster C; Liew DFL; Leung JL; Scott AM; Buchanan RRC
    Int J Rheum Dis; 2021 Jan; 24(1):56-62. PubMed ID: 33043616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adrenal gland hypofunction in active polymyalgia rheumatica. effect of glucocorticoid treatment on adrenal hormones and interleukin 6.
    Cutolo M; Straub RH; Foppiani L; Prete C; Pulsatelli L; Sulli A; Boiardi L; Macchioni P; Giusti M; Pizzorni C; Seriolo B; Salvarani C
    J Rheumatol; 2002 Apr; 29(4):748-56. PubMed ID: 11950017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of (18)F-FDG PET/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment.
    Palard-Novello X; Querellou S; Gouillou M; Saraux A; Marhadour T; Garrigues F; Abgral R; Salaün PY; Devauchelle-Pensec V
    Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):773-9. PubMed ID: 26753600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiling in patients with polymyalgia rheumatica before and after symptom-abolishing glucocorticoid treatment.
    Kreiner FF; Borup R; Nielsen FC; Schjerling P; Galbo H
    BMC Musculoskelet Disord; 2017 Aug; 18(1):341. PubMed ID: 28784116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature.
    Macchioni P; Boiardi L; Catanoso M; Pulsatelli L; Pipitone N; Meliconi R; Salvarani C
    Semin Arthritis Rheum; 2013 Aug; 43(1):113-8. PubMed ID: 23433960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukocyte Dynamics Reveal a Persistent Myeloid Dominance in Giant Cell Arteritis and Polymyalgia Rheumatica.
    van Sleen Y; Graver JC; Abdulahad WH; van der Geest KSM; Boots AMH; Sandovici M; Brouwer E
    Front Immunol; 2019; 10():1981. PubMed ID: 31507597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial.
    Bonelli M; Radner H; Kerschbaumer A; Mrak D; Durechova M; Stieger J; Husic R; Mandl P; Smolen JS; Dejaco C; Aletaha D
    Ann Rheum Dis; 2022 Jun; 81(6):838-844. PubMed ID: 35210264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.